<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424291</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HNP016</org_study_id>
    <nct_id>NCT03424291</nct_id>
  </id_info>
  <brief_title>A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and efficacy of Apatinib in Combination&#xD;
      With Radiotherapy / Chemotherapy for Second-line and Above Recurrent / Metastatic Head and&#xD;
      Neck Squamous Cell Carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Head and neck cancer refers to the skull base to the supraclavicular, cervical spine within&#xD;
      the scope of all malignant tumors is more common in China's malignant tumors. Head and neck&#xD;
      cancer mainly surgery and radiotherapy, chemotherapy alone or in combination therapy, common&#xD;
      head and neck squamous cell carcinoma chemotherapy programs are: PF regimen (cisplatin +&#xD;
      5-fluorouracil), PLF program (cisplatin + carboplatin +5 - fluorouracil), TPF program&#xD;
      (cisplatin + 5 - fluorouracil + paclitaxel) and so on. The researcher consider to add&#xD;
      apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR&#xD;
+ PR + SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response（DOR）</measure>
    <time_frame>up to 2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Apatinib plus chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib plus chemoradiation</intervention_name>
    <description>Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)</description>
    <arm_group_label>Apatinib plus chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 and ≤ 70 years of age.&#xD;
&#xD;
          2. Pathologically confirmed advanced head and neck squamous cell carcinoma, with&#xD;
             measurable lesions (tumor lesions CT scan diameter ≥ 10mm, lymph node lesions CT scan&#xD;
             short diameter ≥ 15mm, the scan layer thickness is not greater than 5mm, measurable&#xD;
             after the lesion recurrence / metastasis Received radiotherapy, frozen and other local&#xD;
             treatment).&#xD;
&#xD;
          3. Patients with recurrent or metastatic head and neck squamous cell carcinoma who have&#xD;
             undergone radiotherapy and chemotherapy to treat disease progression.&#xD;
&#xD;
             Note: adjuvant therapy within 6 months of recurrence, adjuvant therapy is defined as&#xD;
             first-line treatment.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.&#xD;
&#xD;
          5. Life expectancy of more than 6 months.&#xD;
&#xD;
          6. Subjects underwent additional treatment of the damage recovered (NCI-CTCAE Version 4.0&#xD;
             Grading ≤ 1), where the interval between receiving nitrosourea or mitomycin was&gt; 6&#xD;
             weeks; receiving other cytotoxic drugs, bevacizumab (Avastin), radiotherapy or surgery&#xD;
             ≥ 4 weeks; EGFR TKI class of targeted drugs ≥ 2 weeks.&#xD;
&#xD;
          7. Adequate hepatic, renal, heart, and hematologic functions: ANC ≥ 1.5×109/L, PLT ≥&#xD;
             80×109/L, HB ≥ 90 g/L, TBIL ≤ 1.5×ULN, ALT or AST&#xD;
&#xD;
             ≤ 2.5×ULN (or ≤ 5×ULN in patients with liver metastases), Serum Cr ≤ 1.5×ULN, Cr&#xD;
             clearance ≥ 45 mL/min.&#xD;
&#xD;
          8. Women of childbearing age must have had reliable contraception or have had a pregnancy&#xD;
             test (serum or urine) within 7 days prior to enrollment with a negative result and&#xD;
             would be prepared to use the appropriate method of contraception 8 weeks after the&#xD;
             test and the last administration of the test drug. For males, consent is to be given&#xD;
             to contraception or surgical sterilization 8 weeks after the test and the last&#xD;
             administration of the test drug.&#xD;
&#xD;
          9. Signed the informed consent form prior to patient entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-squamous cell carcinoma (including squamous cell carcinoma mixed with other&#xD;
             pathological types), nasopharyngeal carcinoma.&#xD;
&#xD;
          2. Active brain metastases, meningococcal meningitis, patients with spinal cord&#xD;
             compression, or imaging at CT or MRI examination revealed brain or pia mater&#xD;
             disease（Patients who have completed treatment and whose symptoms are stable in the&#xD;
             first 21 days of randomization may be enrolled in the study but may be diagnosed as&#xD;
             having no intracerebral hemorrhage by MRI, CT or venography）.&#xD;
&#xD;
          3. Uncontrollable hypertension (systolic BP ≥140 mmHg or diastolic BP&#xD;
&#xD;
             ≥90 mmHg, despite optimal medical therapy).&#xD;
&#xD;
          4. grade II The above myocardial ischemia or myocardial infarction, poor control of&#xD;
             arrhythmia (including QTc interval male ≥ 450 ms, female ≥ 470 ms); NYHA standards, Ⅲ&#xD;
             ~ Ⅳ grade cardiac insufficiency, or cardiac ultrasound examination prompted left&#xD;
             ventricular ejection Score (LVEF) &lt;50%.&#xD;
&#xD;
          5. Patients whose routine urine tests indicate that urine protein ≥ ++ or verifies that&#xD;
             the 24-h urine protein quantitation ≥ 1.0 g.&#xD;
&#xD;
          6. Patients who had obvious hemoptysis within 2 months before screening, or experienced&#xD;
             daily hemoptysis with a volume more than half a tea spoon (2.5ml) or above.&#xD;
&#xD;
          7. Coagulation dysfunction (INR&gt; 1.5, PT&gt; ULN +4s or APTT&gt; 1.5 ULN), with bleeding&#xD;
             tendency or ongoing thrombolysis or anti-blood coagulation treatment；Patients treated&#xD;
             with anticoagulants or vitamin K antagonists such as warfarin, heparin, or the like.&#xD;
&#xD;
          8. Long-term, unhealed wounds or fractures.&#xD;
&#xD;
          9. Patients who have history of psychotropic substance abuse who can not be abstinent or&#xD;
             who have mental disorders.&#xD;
&#xD;
         10. According to the researchers' judgment, there are other serious patients who are&#xD;
             endangered or have concomitant diseases that affect the completion of the study.&#xD;
&#xD;
         11. Patients with CNS metastases.&#xD;
&#xD;
         12. Pregnant or lactating women.&#xD;
&#xD;
         13. Researchers think it is not suitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hui Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>wei Du</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hui Wu</last_name>
    <phone>13503716710</phone>
    <email>wuhui7008@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hui Wu</last_name>
      <phone>13503716710</phone>
      <email>wuhui7008@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

